Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 4/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10287605 | 0.93 | DRD2 (0.41) | DRD2ADRA1ACCR1DRD4DRD3 | |
| SCHEMBL13824491 | 0.91 | DRD2 (0.38) | DRD2ADRA1ACCR1DRD4DRD3 | |
| SCHEMBL13824256 | 0.90 | DRD2 (0.37) | DRD2ADRA1ACCR1DRD4DRD3 | |
| SCHEMBL13824482 | 0.90 | DRD2 (0.40) | DRD2ADRA1ACCR1DRD4DRD3 | |
| SCHEMBL13616961 | 0.89 | DRD2 (0.36) | DRD2ADRA1ACCR1DRD4DRD3 | |
| SCHEMBL10288236 | 0.88 | ALDH1A1 (0.41) | DRD2CCR1DRD3SIGMAR1 | |
| SCHEMBL12121715 | 0.87 | CCR1 (0.37) | DRD2ADRA1ACCR1DRD4DRD3 | |
| SCHEMBL13617080 | 0.86 | DRD2 (0.36) | DRD2CCR1DRD4DRD3 | |
| SCHEMBL13617506 | 0.86 | DRD2 (0.38) | DRD2ADRA1ACCR1DRD4DRD3 | |
| SCHEMBL12121724 | 0.86 | DRD2 (0.39) | DRD2CCR1DRD4DRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | DRD2 3566/4885ADRA1A 1190/4885CCR1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.